Take Part in Research
See below for opportunities to take part in psoriasis research, or to share your experiences. Please note that these projects are not run by the Psoriasis Association, but by external parties such as academic research departments.
We do not normally advertise commercial clinical trials. If the opportunities below do not match the type of project you are looking to be involved in, you can also take a look at 'Be Part of Research', which is run by the National Institute for Health Research (NIHR) and will give you lots of information about taking part in clinical trials and allow you to search for a relevant trial in your area. More information about clinical trials can also be found on the NHS website and at ClinicalTrials.gov.
Dermatology Patient Advisory Group – NIHR Newcastle BRC
Skin diseases are the most common reason for going to the GP in the UK. Approximately 800,000 people per year are then referred to secondary care dermatologists. The Newcastle BRC Skin, Oral Disease and Immunogenomics theme has active programmes of research involving patients living with multiple long term conditions, skin inflammation and rare diseases involving the skin.
At the NIHR Newcastle BRC, we use the findings from our studies in healthy volunteers as well as in psoriasis, atopic eczema, periodontitis and critical care cohorts, to evaluate the effect of ageing and other age-related co-morbidities (diabetes, hypertension) on inflammatory response, disease evolution and response to treatment.
We are setting up a Dermatology Patient Advisory Group to help to make sure our research is relevant to patients. Using their lived experience, the group will provide feedback and advice to researchers on current research as well as share what is important to them, helping to inform research priorities.
Commitment
You will be asked to attend 2 meetings per year.
Meetings will take place in Newcastle upon Tyne and last for 1-2 hours.
There may be ad hoc meetings or activities throughout each year. This might include additional in-person meetings or providing feedback online via email.
Membership of the group will be for 2 years (2025-2027) in accordance with the current NIHR Newcastle BRC funding award.
Take a look at the role description for more details.
How do I apply?
If you are interested in becoming a member of the group, please complete this short application form:
https://forms.office.com/e/XYGeJ25dKn
The closing date for applications is 02/02/2025
Contact: Katherine Jacques, PPIE Manager – katherine.jacques@newcastle.ac.uk
JAKPPPOT Trial
We are looking for adults with palmoplantar pustulosis, diagnosed by a dermatologist, to take part in the JAKPPPOT trial. During the trial, participants will take a tablet once-a-day for 8 weeks. This tablet will be a janus kinase inhibitor, a new group of drugs that suppresses the immune system. The drug is called upadacitinib (its brand name is ‘Rinvoq’).
Participants will attend our clinic at Guy’s and St Thomas’s NHS Trust, London Bridge, regularly during the 8-week trial, and we will take blood samples at each visit. We will also invite participants to take part in a voluntary interview before and after the 8 weeks of treatment to understand their thoughts on the tablet and the trial more generally.
Participants will need to be over the age of 18, and cannot be pregnant or breast-feeding. Participants will need to stop all UV light related treatment or systemic treatment (medications taken by mouth or injected) that they are currently taking, but they can continue using certain topical treatments (creams/ointments).
Please contact Dr David Gleeson (Principal Investigator) at JAKPPPOT@gstt.nhs.uk to find out more about this study.
Developing a social media intervention to increase awareness and understanding of psoriasis: A mixed-methods project using co-production with adults with psoriasis
Your valuable feedback can help shape this study!
Find out more by getting in touch with Mani via email: emmanuel.toni@uwe.ac.uk
The HIPPOCRATES project
Called the HIPPOCRATES Prospective Observational Study (HPOS), the online study will monitor people with psoriasis over a three-year period to see who develops PsA. It will be completely remote with participants filling in questionnaires online and sending small fingerprick blood samples by prepaid post. Initially looking to recruit the volunteers from the UK, the ultimate goal is to recruit 25,000 people with psoriasis across 12 countries.
The
study is part of wider research called The
HIPPOCRATES project investigating psoriatic arthritis across Europe. It is a large consortium of over 25 research groups across
Europe, led by Professor Oliver FitzGerald in Dublin which aims to answer 4 key research questions around psoriasis
diagnosis, prediction, response to therapies, and prognosis on who will get
joint damage.
If you would like to find out more about the project,
or take part, you can find out more at the HPOS study website
Opportunity for adolescent patients with psoriasis to take part in a trial comparing Risankizumab with Ustekinumab (OptIMMize-1)
***UPDATE - Please note that Parts 1, 2 and 3 of this study are now closed to recruitment. Recruitment for Part 4 of the study has not yet commenced – details will be announced in due course.***
This is an opportunity for 12-17 year old patients with moderate to severe plaque psoriasis. The trial, sponsored by the pharmaceutical company, AbbVie, compares the treatment efficacy and safety of Risankizumab (Skyrizi) vs Ustekinumab (Stelara), two biologic therapies. All participants are guaranteed active treatment, regardless of whether they have had systemic therapy before.
Recruitment criteria (list not exclusive):
- Aged between 12 to < 18 years at the time of enrolment
- Have had a diagnosis of chronic plaque psoriasis for at least 6 months
- Have moderate to severe psoriasis, defined as ≥ 10% Body Surface Area (BSA) psoriasis involvement with a static Physician’s Global Assessment (sPGA) score of ≥ 3, or Psoriasis Area and Severity Index (PASI) ≥ 12
- Erythrodermic psoriasis, generalised or localised pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis;
- Active skin disease other than psoriasis that could interfere with the assessment of psoriasis;
- Clinically significant drug or alcohol abuse within the last 6 months;
- An allergic reaction or hypersensitivity to a biologic agent or its excipients;
- A latex allergy;
- An organ transplant that requires continued immunosuppression;
- Any malignancy except for successfully treated non-melanoma skin cancer or localised carcinoma in situ of the cervix.
- Hepatitis B (HB) (hepatitis B virus [HBV]) or hepatitis C (hepatitis C virus [HCV]) infection;
- Human immunodeficiency virus (HIV), defined as confirmed positive anti-HIV antibody (HIV Ab) test;
- Genetic deficiency in IL-12/IL-23;
- West Ambulatory Care Hospital, Glasgow: Areti.Makrygeorgou@ggc.scot.nhs.uk
- Frimley Park Hospital, Surrey: sara.sherif@nhs.net
- Royal Devon and Exeter Hospital, Devon: naomi.goldstraw@nhs.net
- Derriford Hospital, Plymouth: thurein.newin@nhs.net
- Guy’s and St Thomas’ NHS Foundation Trust, London: please email Eva.Hilger@gstt.nhs.uk or call 07917217601
No history of:
No evidence of:
The following centres are
open for recruitment into the study (please email the investigators directly):
Dr Wedad Abdelrahman,
Chief Investigator
(wedad.abdelrahman@gstt.nhs.uk)
Prof Carsten Flohr,
Study Investigator (carsten.flohr@kcl.ac.uk)
Consultant Paediatric Dermatologists
St John’s Institute of
Dermatology,
Guy’s & St Thomas’
NHS Foundation Trust